InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,399.22
(
-0.51%
)
US TECH 100
18,360.00
(
-0.95%
)
Dow Jones
39,935.07
(
0.20%
)
Brent Oil
81.54
(
0.99%
)
Bitcoin
65,793.69
(
0.64%
)
Post# of 252681
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

lgonber

Send PM Follow Ignore
Followers 12
Posts 648
Boards Moderated 0
Alias Born 12/20/2014

lgonber

Re: None

Monday, 02/22/2016 9:55:07 AM

Monday, February 22, 2016 9:55:07 AM

Post# of 252681
RDUS up 30% on AMGN data
• Radius Health (NASDAQ:RDUS) is up 30% in reaction to Amgen's announcement of Phase 3 data for its osteoporosis candidate romosozumab that showed a 73% reduction in the risk of vertebral fracture in postmenopausal women.
• Radius' candidate, abaloparatide, showed an 83% reduction in vertebral fracture in its Phase 3 ACTIVE study. Its marketing application is currently under review in Europe. It expects to file its NDA in the U.S. in the near future.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up